Browsing by Author "Cotrina-Concha, JM"

Now showing 1 - 8 of 8

ASO Author Reflections: Distilling Wisdom From Two Decades of Cutaneous Malignant Melanoma at a Peruvian Cancer Institute: A Stirring Call for Action
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; Ziegler-Rodriguez, O; De, La, Cruz-Ku, G; Cotrina-Concha, JM; Dunstan, J; Pinillos-Portella, M; Vilchez-Santillan, S; Möller, MG
Resumen disponible en la revista donde esta publicada
Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women
(American Association for Cancer Research Inc., 2022) Zavala Valentin, A; Casavilca-Zambrano, S; Navarro-Vásquez, J; Castaneda-Altamirano, CA; Valencia, G; Morante, Z; Calderón, M; Abugattas-Saba, JE; Gómez-Moreno, HL; Fuentes-Rivera, HA; Liendo-Picoaga, R; Cotrina-Concha, JM; Monge, C; Neciosup, SP; Scott, H; Hu, D; Sánchez, SE; Williams, A; Núñez-Marrero, A; Godoy, L; Hechmer, A; Olshen, AB; Dutil, J; Ziv, E; Zabalet,a J; Gelaye B; Vásquez, J; Gálvez-Nino, M; Enriquez-Vera, D; Vidaurre, T; Fejerman, L
Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53
Association between PIK3CA Mutations in Blood and Tumor-Infiltrating Lymphocytes in Peruvian Breast Cancer Patients
(Asian Pacific Organization for Cancer Prevention, 2022) Castaneda-Altamirano, CA; Castillo-García, M; Bernabe, LA; Suarez, N; Romero, A; Sanchez, J; Torres, E; Enciso, J; Tello, K; Enciso, N; Velarde, M; De La Cruz-Sacasqui, M; Dunstan Yataco, J; Cotrina-Concha, JM; Abugattas-Saba, JE; Pinillos-Portella, MA; Roque, K; Fuentes-Rivera, Hugo; Poquioma-Rojas, E; Guerra, H; Gomez-Moreno, HL
Objective: To evaluate the relationship between circulating tumor DNA (ctDNA) presence and tumor features including tumor-infiltrating lymphocyte (TIL) levels in Peruvian breast cancer patients. Materials and Methods: This was a prospective study conducted at the Instituto Nacional de Enfemedades Neoplasicas, Peru. We evaluated level of TIL and PIK3CA mutations in ctDNA. Clinical characteristics, including outcome data, were collected from the patient file. Survival was calculated from the date of blood sample drawn to the event time. Data collected were analyzed using SPSS software version 25. Results: We analyzed plasma samples from 183 breast cancer patients. most cases were of Luminal-B (44.8%) phenotype and stage II (41.5%), and median stromal TIL was 30%. PIK3CA mutation in ctDNA was detected in 35% cases (most with E545K) and was associated with lower TIL level (p=0.04). PIK3CA in ctDNA tended to be associated with advanced stages (p=0.09) in the whole series and with higher recurrence rates (p=0.053) in the non-metastatic setting. Patients with presence of PIK3CA in ctDNA tended to have shorter survival (p=0.083). Conclusion: Presence of PIK3CA mutation in ctDNA was frequently found in our Peruvian breast cancer series, was associated with lower TIL levels and tended to predict poor outcomes. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
Correction to: Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute (Annals of Surgical Oncology, (2024), 31, 9, (6097-6117), 10.1245/s10434-024-15573-6)
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
In the original online version of this article Luis Piedra‑Delgado's affiliation was incorrect. It is correct as reflected here. The original article was corrected.
Human Papillomavirus, Cytomegalovirus Infection and P16 Staining in Breast Tumors from Peruvian Women
(Asian Pacific Organization for Cancer Prevention, 2022) Calderon-Valencia, G; Castaneda-Altamirano, C; Castillo, M; Sanchez, J; Bernabe, L; Suarez, N; Tello, K; Torres, E; Cotrina-Concha, JM; Dunstan Yataco, J; De-La-Cruz-Sacasqui, M; Abugattas Saba, J; Guerra Miler, H; Manrique Hinojosa, E; Aguayo, F; Gomez Moreno, HL
Objective: To evaluate the frequency distribution of viral infections in Peruvian Breast Cancer (BC) lesions and its association with clinicopathological features. Additionally, a prospective evaluation of p16 and Tumor-infiltrating lymphocytes (TIL) levels were performed for developing a comprehensive analysis. Methods: Detection of high risk- human papillomavirus (HR- HPV) through qPCR was performed in 447 BC and 79 non-cancer frozen samples. Paired paraffin samples from 238 BC were stained with Human cytomegalovirus (HCMV) and p16 immunohistochemistry. TIL was calculated in 397 BC cases. Results: HCMV was positive in 72.5%. HR- HPV was detected in 2.9% of BC and 1.3% of non-malignant samples. P16+ was found in 28.15% and median TIL percentage was 30. HR- HPV infection was associated with non-ductal histology (p=0.003) and p16+ (p=0.017). Positive P16+ was associated with higher T stage (p=0.022), grade (p=0.009), TIL level (p=0.002), and triple-negative phenotype (p=0.021). Conclusion: HCMV is frequent, but HR- HPV infection is unusual in Peruvian BC. P16+ is associated with HR- PVH infection, high TIL and aggressive features. © 2022. All Rights Reserved.
Long-Term Outcomes of an International Cooperative Study of Intraoperative Radiotherapy Upfront Boost With Low Energy X-Rays in Breast Cancer
(Frontiers Media S.A., 2022) Sarria, GR; Ramos, ML; Palacios, A; Del Castillo, R; Castro, F; Calvo, A; Cotrina-Concha, JM; Heredia, A; Galarreta, JA; Fuentes-Rivera, P; Avalos, A; Martinez, DA; Colqui, K; Ziegler, G; Schmeel, LC; Pinillos, LV; Wenz, F; Giordano, FA; Sarria, GJ; Sperk, E
Purpose: The purpose of this study was to assess the effectivity of upfront kilovoltage intraoperative radiotherapy (IORT) as a boost in high-risk early-stage breast cancer patients from an international pooled cohort. Materials/Methods: Patients from four centers in three different countries were retrospectively screened. Those with a minimum 1-year follow-up were included. Cumulative local (LR), regional (RR), and distant metastasis rates (DM) were analyzed. Additionally, the estimated overall survival (OS) was assessed. The Cox regression analysis was performed to identify failure predicting factors. Results: A total of 653 patients from centers in Peru, Spain, and Germany were included. The median follow-up was 55 (12–180) months, and age was 58 (27–86) years. Clinical tumor (T) staging was T1 65.85%, T2 30.17%, and T3 3.98%. Positive margins were found in 7.9% and in-situ component in 20.06%. The median IORT dose was 20 (6–20). The median time from IORT to EBRT was 74.5 (13-364) days. An overall 3.4% (n = 22) of patients developed local recurrence at some point during follow-up. The 12-, 60-, and 120-month cumulative LR were 0.3%, 2.3%, and 7.9%, respectively. After multivariate analysis, only age <50 remained to be a significant prognostic factor for local recurrence (HR 0.19, 95% CI 0.08–0.47 p < 0.05). The 10-year estimated OS was 81.2%. Conclusion: Upfront boost with IORT yields similar local control outcomes to those EBRT-based reports. Results from prospective trials, regarding toxicity, cosmesis, and effectivity are awaited to confirm these findings.
Promoter hypermethylation of RARB and GSTP1 genes in plasma cell-free DNA as breast cancer biomarkers in Peruvian women
(John Wiley and Sons Inc, 2023) Danos, P; Giannoni-Luza, S; Murillo-Carrasco, AG; Acosta, O; Guevara-Fujita, ML; Cotrina-Concha, JM; Guerra-Miller, H; Pinto-Oblitas, J; Aguilar-Cartagena, A; Araujo, JM; Fujita, R; Buleje-Sono, JL
Background: Promoter hypermethylation is one of the enabling mechanisms of hallmarks of cancer. Tumor suppressor genes like RARB and GSTP1 have been reported as hypermethylated in breast cancer tumors compared with normal tissues in several populations. This case–control study aimed to determine the association between the promoter methylation ratio (PMR) of RARB and GSTP1 genes (separately and as a group) with breast cancer and its clinical-pathological variables in Peruvian patients, using a liquid biopsy approach. Methods: A total of 58 breast cancer patients and 58 healthy controls, matched by age, participated in the study. We exacted cell-free DNA (cfDNA) from blood plasma and converted it by bisulfite salts. Methylight PCR was performed to obtain the PMR value of the studied genes. We determined the association between PMR and breast cancer, in addition to other clinicopathological variables. The sensitivity and specificity of the PMR of these genes were obtained. Results: A significant association was not found between breast cancer and the RARB PMR (OR = 1.90; 95% CI [0.62–6.18]; p = 0.210) or the GSTP1 PMR (OR = 6.57; 95% CI [0.75–307.66]; p = 0.114). The combination of the RARB + GSTP1 PMR was associated with breast cancer (OR = 2.81; 95% CI [1.02–8.22]; p = 0.026), controls under 50 years old (p = 0.048), patients older than 50 (p = 0.007), and postmenopausal (p = 0.034). The PMR of both genes showed a specificity of 86.21% and a sensitivity of 31.03%. Conclusion: Promoter hypermethylation of RARB + GSTP1 genes is associated with breast cancer, older age, and postmenopausal Peruvian patients. The methylated promoter of the RARB + GSTP1 genes needs further validation to be used as a biomarker for liquid biopsy and as a recommendation criterion for additional tests in asymptomatic women younger than 50 years.
Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
Introduction: The worldwide incidence of melanoma has increased in the last 40 years. Our aim was to describe the clinic-pathological characteristics and outcomes of three cohorts of patients diagnosed with melanoma in a Latin-American cancer institute during the last 20 years. Methods: We evaluated three retrospective patient cohorts diagnosed with melanoma at Instituto Nacional de Enfermedades Neoplasicas (INEN), a public hospital in Lima, Peru, for the years 2005–2006, 2010–2011, and 2017–2018. Survival rate differences were assessed using the Log-rank test. Results: Overall, 584 patients were included (only trunk and extremities); 51% were male, the mean age was 61 (3–97) years, and 48% of patients resided in rural areas. The mean time to diagnosis was 22.6 months, and the mean Breslow thickness was 7.4 mm (T4). Lower extremity was the most common location (72%). A majority of the patients (55%) had metastases at the time of presentation, with 36% in stage III and 19% in stage IV. Cohorts were distributed as 2005–2006 (n = 171), 2010–2011 (n = 223), and 2017–2018 (n = 190). No immunotherapy was used. Cohort C exhibited the most significant increase in stage IV diagnoses (12.3%, 15.7%, 28.4%, respectively; p < 0.01). The median overall survival rates at the three-year follow-up demonstrated a decline over the years for stages II (97%, 98%, 57%, respectively; p < 0.05) and III (66%, 77%, 37%; p < 0.01). Conclusions: There has been a worsening in the incidence of late-stage metastatic melanoma in Peru throughout the years, coupled with a significant decline in overall survival rates. This is underscored by the fact that half of the population lives in regions devoid of oncological access.